Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia

PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Severe Thrombocytopenia
Interventions
DRUG

oprelvekin

injection, 50 mg/kg, once daily

Trial Locations (14)

20060

Howard University, Washington D.C.

Pfizer Investigational Site, Washington D.C.

40353

Montgomery Cancer Center, Mount Sterling

Pfizer Investigational Site, Mount Sterling

44622

Gabrail Cancer Center Research, Dover

Pfizer Investigational Site, Dover

44718

Gabrail Cancer Center Research, Canton

Pfizer Investigational Site, Canton

45042

Pfizer Investigational Site, Middletown

Signal Point Clinical Research Center, LLC, Middletown

78041

Pfizer Investigational Site, Laredo

South Texas Research Alliance LLC., Laredo

90403

Pfizer Investigational Site, Santa Monica

Sarcoma Oncology Center, Santa Monica

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY